^
    Back
    Association details:
    Biomarker:TAF15-CHN1 translocation
    Cancer:Osteosarcoma
    Drug:seclidemstat (SP2577) (LSD1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASCO 2021
    Title:

    Preliminary efficacy from an ongoing phase 1 dose escalation study of seclidemstat (SP-2577) in patients (pts) with advanced solid tumors (AST).

    Published date:
    05/19/2021
    Excerpt:
    SALA-003-AC19 (NCT03895684) is a phase 1 trial of single agent SP-2577 in pts with AST...19 pts with AST (10 sarcoma, 2 prostate, 2 ovarian, 2 pancreatic, 1 renal, 1 cervical, 1 breast) were enrolled….Extra-skeletal myxoid chondrosarcoma...TAF15-CHN…Best overall response...SD...
    DOI:
    10.1200/JCO.2021.39.15_suppl.3073
    Trial ID:
    SALA-003-AC19